Capula Management’s Edwards Lifesciences EW Stock Holding History

Capula Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-460	Closed	-$36.8K	–	858
2026 Q1	$36.8K	Buy	+460	New	+$37.9K	﹤0.01%	1017
2023 Q1	–	Sell	-12,920	Closed	-$964K	–	780
2022 Q4	$964K	Buy	12,920 +7,470	+137%	+$576K	0.01%	428
2022 Q3	$450K	Buy	+5,450	New	+$524K	0.01%	492
2021 Q4	–	Sell	-8,130	Closed	-$920K	–	402
2021 Q3	$920K	Buy	8,130 +5,288	+186%	+$604K	0.01%	544
2021 Q2	$294K	Buy	+2,842	New	+$268K	﹤0.01%	581

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Capula Management's EW Position: Q2 2026 in Review

Capula Management sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 460 shares — an estimated $36.8K sold.

Capula Management first reported a position in EW in Q2 2021 and held it in 5 quarters. The position peaked at $964K in Q4 2022. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Capula Management reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
Capula Management sold 460 Edwards Lifesciences shares in Q2 2026, an estimated $36.8K.
Capula Management first reported a position in Edwards Lifesciences in Q2 2021 and held it in 5 quarters.
Capula Management's Edwards Lifesciences position peaked at $964K in Q4 2022.
1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.